Key Takeaways Edwards Lifesciences sees growth in Surgical Structural Heart, led by RESILIA tissue adoption.EW's TAVR and TMTT segments posted strong Q3 gains supported by new approvals and global rollouts.Macro pressures, higher COGS and ongoing litigation continue to challenge Edwards' profitability.Edwards Lifesciences Corporation (EW) is well-poised to grow in the coming quarters owing to its Surgical Structural Heart, which pioneered the RESILIA tissue. The company’s Transcatheter Aortic Valve Replacem ...

Edwards Lifesciences 2025 Investor Conference 2025 Investor Conference Mark Wilterding Cautionary Statement Presentations and comments made today by management of Edwards Lifesciences Corporation (the "Company") will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can sometimes be identified by the use of words, such as "may," "will," "should," ...